Kura Oncology

Kura Oncology is a clinical-stage American biopharmaceutical company focused on the discovery and development of small-molecule precision medicines for the treatment of cancer. The company was founded in 2014 and is headquartered in San Diego, California, where it carries out research and clinical development. It is publicly traded on the Nasdaq Global Select Market under the ticker symbol KURA. Kura's pipeline centers on targeted oncology agents rather than conventional cytotoxic chemotherapy. Its best-known programs include ziftomenib, an oral menin inhibitor being developed for acute myeloid leukemia (AML) and other leukemias bearing KMT2A rearrangements or NPM1 mutations, and tipifarnib, an oral farnesyltransferase inhibitor studied in head and neck squamous cell carcinoma and other tumors with HRAS mutations. The company has also advanced earlier-stage assets in its precision oncology portfolio. As a clinical-stage company, Kura does not yet market approved products at scale; its revenue model depends on successful clinical trials, regulatory approvals, and potential partnerships or licensing arrangements with larger pharmaceutical companies. The company has funded its programs through public equity offerings and strategic collaborations, and it operates in the highly competitive oncology drug development space alongside large pharmaceutical firms and other biotechs. Kura positions itself as a precision-medicine specialist, emphasizing biomarker-driven patient selection and oral, well-tolerated agents that can address unmet needs in hematologic malignancies and genetically defined solid tumors. Its brand identity is tied to scientific rigor in translational oncology and to the promise of targeted therapies for patients with limited treatment options.

Kura Oncology was founded in 2014 as a clinical-stage biopharmaceutical company dedicated to precision oncology. It established its headquarters in San Diego, California, and built its strategy around small-molecule drugs that target specific genetic alterations driving cancer growth. The company's early identity was closely tied to tipifarnib, an oral farnesyltransferase inhibitor that Kura repositioned for genetically defined patient populations, notably head and neck squamous cell carcinoma harboring HRAS mutations. This biomarker-driven approach became a hallmark of the company's development philosophy. Kura subsequently expanded its pipeline with ziftomenib, an oral menin inhibitor targeting KMT2A-rearranged and NPM1-mutant leukemias, including acute myeloid leukemia. Ziftomenib became a central program for the company and advanced through clinical development, including combination studies in AML. The company went public on Nasdaq under the ticker KURA, using public equity markets to fund its clinical programs. Over time it has also pursued collaborations and licensing arrangements to support development and potential commercialization. As of the mid-2020s, Kura remains a clinical-stage company whose value and brand reputation rest on the progress of its targeted oncology pipeline toward regulatory approval.

• 2014

  Kura Oncology founded as a clinical-stage precision oncology company.

• Company lists on Nasdaq under ticker KURA.

• Ziftomenib advances into clinical development for acute myeloid leukemia.

Clinical-stage precision oncology company developing oral, biomarker-driven targeted cancer therapies.

• ziftomenib

  Oral menin inhibitor in development for KMT2A-rearranged and NPM1-mutant leukemias, including AML.

• tipifarnib

  Oral farnesyltransferase inhibitor studied in HRAS-mutant head and neck squamous cell carcinoma and other tumors.

1. 1Kura Oncology official websitekuraoncology.com
2. 2Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitorthemarketsdaily.com